Neuro-oncology

GENT-15. INTEGRATED MOLECULAR PROFILING OF HUMAN BRAIN TUMORS THROUGH MULTIOMIC ANALYSIS OF SERIAL SECTIONS (MASS).

Neuro-oncology

Samuel J. Shelton, Brett E. Johnson, Tali Mazor, Matthew B. Potts, Michael F. McDermott, Eric J. Huang, Dan Lim, Russel O. Pieper, Mitchel S. Berger, Joanna J. Phillips, Joseph F. Costello, Michael C. Oldham

Betacellulin drives therapy resistance in glioblastoma.

Neuro-oncology

Fan Q, An Z, Wong RA, Luo X, Lu ED, Baldwin A, Mayekar MK, Haderk F, Shokat KM, Bivona TG, Weiss WA

The benefit of early surgery on overall survival in incidental low-grade glioma patients: A multicenter study.

Neuro-oncology

Ius T, Ng S, Young JS, Tomasino B, Polano M, Ben-Israel D, Kelly JJP, Skrap M, Duffau H, Berger MS

Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement ('low grade appearance') - a report of the RANO resect group.

Neuro-oncology

Karschnia P, Dietrich J, Bruno F, Dono A, Juenger ST, Teske N, Young JS, Sciortino T, Häni L, van den Bent M, Weller M, Vogelbaum MA, Morshed RA, Haddad AF, Molinaro AM, Tandon N, Beck J, Schnell O, Bello L, Hervey-Jumper S, Thon N, Grau SJ, Esquenazi Y, Rudà R, Chang SM, Berger MS, Cahill DP, Tonn JC

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.

Neuro-oncology

Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, Wong TZ, Zalutsky MR, Pastan I, Bigner DD

Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific.

Neuro-oncology

Jun P, Hong C, Lal A, Wong JM, McDermott MW, Bollen AW, Plass C, Held WA, Smiraglia DJ, Costello JF

Na?/K?-ATPase �2-subunit (AMOG) expression abrogates invasion of glioblastoma-derived brain tumor-initiating cells.

Neuro-oncology

Sun MZ, Kim JM, Oh MC, Safaee M, Kaur G, Clark AJ, Bloch O, Ivan ME, Kaur R, Oh T, Fouse SD, Phillips JJ, Berger MS, Parsa AT

Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.

Neuro-oncology

Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM

Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas.

Neuro-oncology

Cluceru J, Nelson SJ, Wen Q, Phillips JJ, Shai A, Molinaro AM, Alcaide-Leon P, Olson MP, Nair D, LaFontaine M, Chunduru P, Villanueva-Meyer JE, Cha S, Chang SM, Berger MS, Lupo JM

Pages